Cases in primary care laboratory medicine: Pitfalls of testing and summary of guidance on safety monitoring with amiodarone and digoxin

British Medical Journal

Volumn 334, Issue 7588, 2007, Pages 312-315

  Smellie, W Stuart A ^a   Coleman, Jamie J ^b  

^a BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTITHYROID AGENT; CARDIOVASCULAR AGENT; DIGOXIN; GLYCEROPHOSPHATE; LIOTHYRONINE; MAGNESIUM; MAGNESIUM SULFATE; PERINDOPRIL; SOTALOL; THYROTROPIN; WARFARIN; ANTIARRHYTHMIC AGENT;

AGED; ANAMNESIS; ANKLE EDEMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; MALE; NAUSEA; PATIENT COMPLIANCE; PATIENT SAFETY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; VITAL SIGN; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; REVIEW; SAFETY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DIGOXIN; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; SAFETY MANAGEMENT;

EID: 33847164406     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39090.709537.47     Document Type: Article

References (18)

1. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Pharmacoepidemiology and drug utilisation. Monitoring amiodarone's toxicities: recommendations, evidence and clinical practice. Clin Pharmacol Ther 2004;75:110-22.
2. Canas F, Tanasijevic M, Ma'luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med 1999;159:363-8.
3. Schoenenberger R, Tanasijevic M, Jha A, Bates D. Appropriateness of antiepileptic drug level monitoring. JAMA 1995;274:1622-6.
4. Eagles J, McCann I Macleod T, Paterson N. Lithium monitoring before and after the distribution of clinical practice guidelines. Acta Psychiatr Scand 2000;101:349-53.
5. Reid LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monitoring 1990;12:72-8.
6. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-threatening electrolyte abnormalities. Circulation 2005;112(suppl 24):IV121-5.
7. Litonjua MR, Penton S, Robinson C, Daubert GP. Digoxin: the monarch of cardiac toxicities. J Pharm Pract 2005;18:157-68.
8. Martin BJ, McAlpine JK, Devine BL. Hypomagnesaemia in elderly digitalised patients. Scott Med J 1988;33:273-4.
9. Young IS, Goh EM, McKillop UH, Stanford CF, Nicholls DP, Trimble ER. Magnesium status and digoxin toxicity. Br J Pharmacol 1991;32:717-21.
10. Smellie WSA, Forth J, Sundar S, Kalu E, McNulty CAM, Sherriff E, et al. Best practice in primary care pathology. Review 4. J Clin Pathol 2006;59:893-902.
11. Drug Interactions: cardiac glycosides. British National Formulary March 2006;52(Appendix1):685-6.
12. Aronson JK, Hardman M, Reynolds DJ. ABC of monitoring drug therapy: digoxin. BMJ 1992;305:1215-8.
13. Cantu TG, Ellerbeck EF, Yun SW, Castine SD, Kornhouser DM. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 1992;49:2944-8.
14. Hanna FWF, Lazarus JH, Scanlon MF, Controversial aspects of thyroid disease. BMJ 1999;319:894-9.
15. Hallworth M, Capps N. Individual drugs: amiodarone. In: Therapeutic drug monitoring and clinical chemistry. London: ACB Venture Publications 1993:35-7.
16. Butler J, Pope R.Thyroid dysfunction. In: Marshall WJ, Banger SK, eds. Clinical biochemistry - metabolic and clinical aspects. Edinburgh: Churchill Livingstone, 1995:331-54.
17. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002;121:19-23.
18. Solomon DH, Hideki H, Daltroy L, Liang MH. Techniques to improve physicians' use of diagnostic tests. JAMA 1998;280:2020-7.